Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1–7 trials

  1. Aroda, V.R.
  2. Ahmann, A.
  3. Cariou, B.
  4. Chow, F.
  5. Davies, M.J.
  6. Jódar, E.
  7. Mehta, R.
  8. Woo, V.
  9. Lingvay, I.
Revue:
Diabetes and Metabolism

ISSN: 1878-1780 1262-3636

Année de publication: 2019

Volumen: 45

Número: 5

Pages: 409-418

Type: Révision

DOI: 10.1016/J.DIABET.2018.12.001 GOOGLE SCHOLAR